Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®; - CMS streamlines reimbursement for DAXXIFY with assignment of permanent J-code -; ; - Peer-reviewed publication of DAXXIFY pivotal data in therapeutics reinforces the products long duration of effect and favorable safety profile -

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): By:Investors Revance Therapeutics, Inc.: Jessica Serr
  • Source:
    Business Wire, February 2, 2024, 7pp
  • Additional Information
    • Abstract:
      Revance Therapeutics, Inc. (RVNC) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J code (J0589) for DAXXIFY®, indicated for the treatment of cervical dystonia in adults. J Codes are product specific reimbursement codes used by commercial insurance plans, Medicare, and other government payers and are intended to simplify reimbursement for providers and expand access for patients...